The Global Drug sales of Cosentyx stood at USD 4,788 Millions in 2022
The indicator recorded a historical growth (CAGR) of10% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Secukinumab (Cosentyx) is an immunosuppressive agent. It is formulated as freeze-dried preparation for powder for solution and solution in prefilled syringe or pre-filled pen for subcutaneous route of administration.
Mechanism of Action
Secukinumab selectively neutralizes interleukin-17A. Interleukin-17A is a key pro-inflammatory cytokine expressed by TH17 cells. Interleukin-17A (IL-17A) is a CD4+ T cell-derived cytokine that promotes inflammatory responses and is elevated in rheumatoid arthritis (RA), asthma, multiple sclerosis, psoriasis, and transplant rejection. So neutralizing effect of the drug on IL-17A helps in treating autoimmune disorders. IL-17A does not play a role in physiological bone remodelling. IL-17A is secreted by Th17 cells under inflammatory conditions. IL-17A upregulates RANK in osteoclast precursors, sensitizing them to RANKL-induced bone resorption. IL-17A is a suitable target to combat bone loss in inflammatory arthritis and autoimmune diseases such as RA.
Cosentyx Overview
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy; adult patients with active psoriatic arthritis and with active ankylosing spondylitis. It is also indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nraxSpA) with objective signs of inflammation and also indicated for the treatment of psoriasis vulgaris, psoriatic arthritis, and pustular psoriasis in children. Cosentyx is marketed for several other indications including Asthma, Pyoderma Gangrenosum, Alopecia Areata, Coronavirus Disease 2019 (COVID-19) Pneumonia, Hidradenitis Suppurativa, Lupus Nephritis, Uveitis, Ankylosing Spondylitis (Bekhterev's Disease), Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Non Alcoholic Fatty Liver Disease (NAFLD), Atopic Dermatitis (Atopic Eczema), Type 1 Diabetes (Juvenile Diabetes), Crohn's Disease (Regional Enteritis), Skin Rash, and Keratoconjunctivitis Sicca (Dry Eye).
Cosentyx was first approved in 2014 and is sold globally including the US, the UK, France, Germany, and Japan by Novartis AG and its subsidiaries. Cosentyx drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward